ENGENE THERAPEUTICS INC (ENGN) Fundamental Analysis & Valuation

NASDAQ:ENGN • CA29286M1059

Current stock price

7.76 USD
+0.16 (+2.11%)
At close:
7.76 USD
0 (0%)
After Hours:

This ENGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ENGN Profitability Analysis

1.1 Basic Checks

  • ENGN had negative earnings in the past year.
  • ENGN had a negative operating cash flow in the past year.
  • In the past 5 years ENGN reported 4 times negative net income.
  • ENGN had a negative operating cash flow in each of the past 5 years.
ENGN Yearly Net Income VS EBIT VS OCF VS FCFENGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • ENGN has a Return On Assets (-36.32%) which is comparable to the rest of the industry.
  • With a decent Return On Equity value of -43.49%, ENGN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -36.32%
ROE -43.49%
ROIC N/A
ROA(3y)-23.55%
ROA(5y)-43.78%
ROE(3y)-30.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENGN Yearly ROA, ROE, ROICENGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 2K 4K 6K

1.3 Margins

  • ENGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENGN Yearly Profit, Operating, Gross MarginsENGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ENGN Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ENGN has more shares outstanding
  • Compared to 1 year ago, ENGN has a worse debt to assets ratio.
ENGN Yearly Shares OutstandingENGN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
ENGN Yearly Total Debt VS Total AssetsENGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • ENGN has an Altman-Z score of 3.52. This indicates that ENGN is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.52, ENGN is doing good in the industry, outperforming 69.77% of the companies in the same industry.
  • ENGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ENGN (0.09) is worse than 62.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.52
ROIC/WACCN/A
WACCN/A
ENGN Yearly LT Debt VS Equity VS FCFENGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 11.75 indicates that ENGN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 11.75, ENGN belongs to the top of the industry, outperforming 84.50% of the companies in the same industry.
  • ENGN has a Quick Ratio of 11.75. This indicates that ENGN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 11.75, ENGN belongs to the top of the industry, outperforming 84.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.75
Quick Ratio 11.75
ENGN Yearly Current Assets VS Current LiabilitesENGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ENGN Growth Analysis

3.1 Past

  • The earnings per share for ENGN have decreased strongly by -48.03% in the last year.
EPS 1Y (TTM)-48.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ENGN will show a very strong growth in Earnings Per Share. The EPS will grow by 21.62% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.94%
EPS Next 2Y6.12%
EPS Next 3Y11.31%
EPS Next 5Y21.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENGN Yearly Revenue VS EstimatesENGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ENGN Yearly EPS VS EstimatesENGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. ENGN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENGN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENGN Price Earnings VS Forward Price EarningsENGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENGN Per share dataENGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.12%
EPS Next 3Y11.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENGN Dividend Analysis

5.1 Amount

  • ENGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENGN Fundamentals: All Metrics, Ratios and Statistics

ENGENE THERAPEUTICS INC

NASDAQ:ENGN (4/15/2026, 8:00:02 PM)

After market: 7.76 0 (0%)

7.76

+0.16 (+2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)06-01
Inst Owners89.29%
Inst Owner Change0%
Ins Owners0.09%
Ins Owner Change0%
Market Cap519.84M
Revenue(TTM)N/A
Net Income(TTM)-122.44M
Analysts86.67
Price Target24.82 (219.85%)
Short Float %1.88%
Short Ratio3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.51%
Min EPS beat(2)-25.95%
Max EPS beat(2)22.94%
EPS beat(4)1
Avg EPS beat(4)-3.73%
Min EPS beat(4)-25.95%
Max EPS beat(4)22.94%
EPS beat(8)3
Avg EPS beat(8)-6.97%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.24%
PT rev (3m)2.55%
EPS NQ rev (1m)9.35%
EPS NQ rev (3m)18.14%
EPS NY rev (1m)18.2%
EPS NY rev (3m)15.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.85
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-1.55
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS0
BVpS4.2
TBVpS4.2
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -36.32%
ROE -43.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.55%
ROA(5y)-43.78%
ROE(3y)-30.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.75
Quick Ratio 11.75
Altman-Z 3.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)253.28%
Cap/Depr(5y)183.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y9.94%
EPS Next 2Y6.12%
EPS Next 3Y11.31%
EPS Next 5Y21.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-63.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.38%
EBIT Next 3Y2.98%
EBIT Next 5Y23.79%
FCF growth 1Y-1143.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1206.71%
OCF growth 3YN/A
OCF growth 5YN/A

ENGENE THERAPEUTICS INC / ENGN Fundamental Analysis FAQ

What is the fundamental rating for ENGN stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENGN.


What is the valuation status of ENGENE THERAPEUTICS INC (ENGN) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENGENE THERAPEUTICS INC (ENGN). This can be considered as Overvalued.


Can you provide the profitability details for ENGENE THERAPEUTICS INC?

ENGENE THERAPEUTICS INC (ENGN) has a profitability rating of 1 / 10.


What is the expected EPS growth for ENGENE THERAPEUTICS INC (ENGN) stock?

The Earnings per Share (EPS) of ENGENE THERAPEUTICS INC (ENGN) is expected to grow by 9.94% in the next year.